CORRECTION: Elanco Animal Health Q2 2024 Adj. EPS $0.30 Beats $0.24 Estimate, Sales $1.184B Beat $1.156B Estimate
Portfolio Pulse from Benzinga Newsdesk
Elanco Animal Health (NYSE:ELAN) reported Q2 2024 adjusted EPS of $0.30, beating the $0.24 estimate by 25%. Sales were $1.184 billion, surpassing the $1.156 billion estimate by 2.40%. This represents a 66.67% increase in EPS and a 12.02% increase in sales compared to the same period last year.
August 08, 2024 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elanco Animal Health reported strong Q2 2024 results with EPS of $0.30 beating estimates by 25% and sales of $1.184 billion beating estimates by 2.40%. EPS increased by 66.67% and sales by 12.02% year-over-year.
Elanco's strong earnings and sales performance, significantly beating analyst estimates, is likely to positively impact its stock price in the short term. The substantial year-over-year growth in both EPS and sales further supports a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100